SVB Securities analyst Thomas Smith reiterated a Buy rating on Equillium (EQ – Research Report) on May 11 and set a price target of $7.00. The company’s shares closed last Friday at $0.58.
Smith covers the Healthcare sector, focusing on stocks such as Immunic, Dice Therapeutics, and Celldex. According to TipRanks, Smith has an average return of 39.8% and a 49.54% success rate on recommended stocks.
Equillium has an analyst consensus of Strong Buy, with a price target consensus of $5.58, an 858.76% upside from current levels. In a report released on May 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Equillium’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $8.88 million and a GAAP net loss of $3.94 million. In comparison, last year the company had a GAAP net loss of $37.42 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
Read More on EQ:
